02Mar 2018

CLINICAL AND BIOCHEMICAL STUDY OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE.

  • Department of Internal Medicine- Faculty of Medicine- South Valley University, Qena-Egypt.
  • Department of Clinical Pathology- Faculty of Medicine- South Valley University, Qena-Egypt.
  • Department of Medical Biochemistry-Faculty of Medicine- South Valley University, Qena-Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Understanding the contributory role of increased fibroblast growth factor23 (FGF23) and secondary hyperparathyroidism to changes in minerals and bone metabolism among chronic kidney disease (CKD) patients is a challenge. So the present study aimed to evaluate the role of FGF23 in CKD of various grades and potential utility for early diagnosis of disturbed bone and mineral metabolism among such patients. This hospital based-cross sectional study has been conducted on 100 CKD patients of various grades. Colorimetric assays of serum urea, creatinine, phosphorous and calcium, while, ELISA assays of parathormone hormone (PTH) and FGF23, were done to all included patients. The overall results showed frequent abnormally high serum FGF23 among CKD grade 3 and 4 compared to other grades. Also there was significant positive correlation between the serum FGF234 levels and the CKD grade (r=0.21, p = 0.03). Significant positive correlations between serum levels of FGF23 vs. both urea and PTH (r=0.19, p=0.04 and r= 0.31, p=0.002 respectively) with significant negative correlations between serum FGF23 levels vs. both total calcium and eGFR (r=-0.21, p=0.02 and r=- 0.39, p=0.0001 respectively). There were non-significant correlations between serum FGF23 and age, weight, height, BMI and phosphorous (p˃0.05). FGF23 is better negative than positive predictive biomarker for calcium and phosphorous disturbances in CKD patients at cut off point 2.9 and 3.1 pg/ml respectively. In conclusion, FGF23 is an emerging biomarker in CKD and its follow up measurement could be helpful for early diagnosis of CKD-MBD.

  1. Wolf M (2012). Update on fibroblast growth factor 23 in chronic kidney disease.?Kidney Int 82:737-747.
  2. Moe S, Drueke T, Cunningham J, et al (2006). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945-53.
  3. Silver J, Rodriguez M, Slatopolsky E (2012).?FGF23 and PTH: double agents at the heart of CKD.?Nephrol. Dial. Transplant 27: 1715?1720 .
  4. Diniz H,?Fraz?o JM (2013). The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.Nefrologia13;33:835-44
  5. Liu S, Zhou J, Tang W, et al (2006). Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:38-49.
  6. Komaba H (2010). CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder).Role of FGF23-Klotho axis in CKD-MBD .Clin Calcium20:1028-1036.
  7. Nakai K,?Komaba H,?Fukagawa M (2010). New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol23:619-625.
  8. Olauson H,?Vervloet MG,?Cozzolino M,?et al (2014). New insights into the FGF23-Klotho axis.Semin Nephrol34: 586-597
  1. Levey A, Coresh J, Balk E, et al (2003). National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137-147.
  2. Raju D, Lalitha D, Kiranmayi P (2012). Observation of estimated GFR in the assessment of chronic kidney disease: application and practice. Asian J Pharm Clin Res 5: 201-206.
  3. Tentori F, Blayney MJ, Albert JM, et al (2008). Mortality risk for dialysis patients With different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS).American Journal of Kidney Diseases 52: 519?530.
  4. Larsson T, Nisbeth U, Ljunggren O, et al (2003). Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272?2279
  5. Gutierrez O, Isakova T, Rhee E, et al (2005). Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205?2215.
  6. Tsai MH, Leu JG, Fang YW, et al (2016). High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.?Medicine 95:e3049.
  7. Semba RD, Fink JC, Sun K, et al (2012). Serum Fibroblast Growth Factor-23 and Risk of Incident Chronic Kidney Disease in Older Community-Dwelling Women. CJASN 7:85-91.
  8. Isakova T, Xie H, Yang W, et al (2011). Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 305: 2432?2439.
  9. Russo D, Battaglia Y (2011). Clinical significance of FGF-23 in patients with CKD. Int J Nephrol 2011: 364890.
  10. Chathoth S, Al-Mueilo S, Cyrus C, et al (2015). Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients.?Cardiorenal Medicine 6:73-82.
  11. Yaghoubi F, Ahmadi F, Lesanpezeshki M, et al (2016). A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis.?Journal of Renal Injury Prevention 5:104-107.
  12. Liu D, Alvarez-El?as AC, Wile B, et al (2017). Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.?BMC Nephrology 18:204.

[Mohamed A. Alsenbesy, Abdel-Kader A. Hashim, Abdallah E. Mohamed and Mohammed H. Hassan. (2018); CLINICAL AND BIOCHEMICAL STUDY OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE. Int. J. of Adv. Res. 6 (Mar). 334-340] (ISSN 2320-5407). www.journalijar.com

Mohammed H. Hassan
Department of Medical Biochemistry-Faculty of Medicine- South Valley University, Qena-Egypt.

DOI:

Article DOI: 10.21474/IJAR01/6683      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6683

Download Full Paper

Download PDF No. of Downloads: 4 | No. of Views: 74